Novo Nordisk reaches exclusive agreement to market Vagifem 10 mcg
 

Novo Nordisk Inc. today announced that it has signed an exclusive agreement with Upsher-Smith Laboratories, Inc. to market Vagifem (estradiol vaginal tablets) 10 mcg. Under the terms of the agreement, Upsher-Smith will exclusively market Vagifem 10 mcg to physicians in the U.S. beginning August 2 through the company's existing field sales force.

More...